House Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Tauzin Says
Executive Summary
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated